Ozempic & GLP-1 Drug Litigation:
MDL 3094 Expands as Discovery Intensifies
Thousands of patients who suffered gastroparesis, intestinal obstruction, and severe GI injuries after using Ozempic, Wegovy, Mounjaro, and related drugs are now part of a rapidly expanding federal MDL. Bellwether trials are expected in 2027. Our firm is accepting cases nationwide.
Drugs Involved
Which GLP-1 Drugs Are Part of MDL 3094?
The MDL consolidates claims involving the major GLP-1 receptor agonists currently on the market, manufactured primarily by Novo Nordisk and Eli Lilly. If you were prescribed any of these drugs and suffered a serious GI injury, you may have a claim.
Where the MDL Stands
MDL 3094: Phase-by-Phase Status
The court has issued early case-management orders and the parties are deep into discovery. The next major milestone — Daubert challenges on gastroparesis causation — will determine how expert testimony is presented to juries and heavily influence settlement leverage.
MDL Created
JPML created MDL 3094 in the Eastern District of Pennsylvania in 2024.
Case Management Orders
Early CMOs issued; preemption and labeling motions largely resolved in plaintiffs’ favor.
Pharmacovigilance Discovery
Production of internal safety-signal analyses, adverse-event reports, and prescriber depositions underway.
Daubert / Rule 702
Expert battles on gastroparesis and GI motility disorder causation will shape the trial landscape.
Bellwether Trials
Early test cases will establish case values and drive settlement negotiations.
Latest Developments · 2025–2026
What Is Happening in the MDL Right Now
MDL 3094 is in active discovery with Daubert and bellwether positioning on the horizon. The case count has grown into the thousands, and the pace of new filings shows no sign of slowing.
- Thousands of cases pending — and growing rapidly as more patients connect their GI diagnoses to GLP-1 drug use
- Pharmacovigilance discovery active — plaintiffs are receiving internal documents on drug safety signals and adverse-event reporting submitted to the FDA
- Plaintiff and prescriber depositions underway — early bellwether pool deponents are being scheduled and examined
- Core failure-to-warn theories intact — early Rule 12(b)(6) motions focused on preemption and labeling challenges have largely been resolved in plaintiffs’ favor
- Daubert briefing approaching — causation battles on gastroparesis and motility disorders will be the next major inflection point
- Bellwether trials expected in 2027 — early verdicts will set the standard for case values across the MDL
Eligibility
Injuries Linked to Ozempic & GLP-1 Drugs
You may qualify if you used Ozempic, Wegovy, Mounjaro, or a related GLP-1 drug and were subsequently diagnosed with a serious gastrointestinal condition. Both patients using these drugs for diabetes management and those using them for weight loss may be eligible.
Qualifying Diagnoses
- Gastroparesis (stomach paralysis)
- Intestinal obstruction or ileus
- Cyclic vomiting syndrome
- Pancreatitis (acute or chronic)
- Gallbladder disease or cholecystitis
- Severe GI motility disorders
General Eligibility Factors
- Prescribed Ozempic, Wegovy, Mounjaro, Zepbound, or related GLP-1 drug
- Used for diabetes management or weight loss
- Developed a qualifying GI diagnosis during or after use
- Diagnosis confirmed and documented by a physician
Our Firm Is Now Accepting Ozempic & GLP-1 Cases
We represent patients nationwide who suffered serious injuries after using GLP-1 drugs. We stay on top of every MDL development — from pharmacovigilance discovery to Daubert rulings to bellwether selections — to ensure our clients receive the strongest possible representation and maximum recovery.
We handle these cases on a contingency fee basis — you pay nothing unless we win.